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Abstract
Background: Published studies have yielded inconsistent results on the relationship between p53 status and the
progression of stage T1 non-muscle invasive bladder cancer (NMIBC). Therefore, we performed a meta-analysis to
evaluate the prognostic value of p53 in T1 NMIBC.
Methods: We systematically searched for relevant literatures in MEDLINE, EMBASE, and Web of Science. Data were
pooled together from individual studies, and meta-analysis was performed. Study quality was assessed using the
Newcastle-Ottawa Scale. Pooled risk ratios (RRs) and 95 % CI were calculated to estimate the effect sizes. Moreover,
subgroup analyses were carried out.
Results: A total of 12 studies comprising 712 patients were subjected to the final analysis. p53 overexpression was
significantly associated with higher progression rate of T1 NMIBC (RR 2.32, 95 % CI 1.59–3.38). Moderate
heterogeneity was observed across the studies (I2 = 39 %, P < 0.0001). In a subgroup analysis stratified by stage, p53
overexpression was a predictor of progression in T1 grade 3 NMIBC (RR 2.71, 95 % CI 1.31–5.64). In addition, in a
subgroup analysis stratified by intravesical therapy, p53 overexpression was a predictor of progression in T1 NMIBC
received Bacillus Calmette-Guérin intravesical therapy (RR 3.35, 95 % CI 1.89–5.93). Furthermore, after excluding the
study that possibly contributed to the heterogeneity by the sensitivity analysis, the association p53 overexpression
was significantly correlated with progression of T1 NMIBC (RR 2.74, 95 % CI 2.05–3.65) without evidence of
heterogeneity (I2 = 0 %, P < 0.0001).
Conclusions: This meta-analysis suggested that p53 overexpression may be associated with progression of T1
NMIBC patients. Because of the heterogeneity and other limitations, further studies with rigid criteria and large
populations are still warranted to confirm our findings.
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Background
There are 386,000 new cases of bladder cancer world-
wide every year and caused 150,000 cancer-specific
deaths [1]. Approximately 70 % of bladder cancer are
non-muscle invasive bladder cancers (NMIBCs) at the
time of presentation [2], and stage T1 disease showing
invasion of the lamina propria present 25 % of NMIBC
[3]. T1 NMIBC represent a clinical challenge because
they are inherently aggressive and have heterogeneous
outcomes. Up to 50 % of T1 NMIBC managed with intra-
vesical therapy progress to muscle invasive BC (MIBC)
within 5 years [4]. Progression rather than recurrence has
been associated with increased chance of metastasis and
death from systemic disease. The European Organisation
for Research and Treatment of Cancer (EORTC) has pro-
posed a scoring system for predicting progression of
NMIBC using a weighted variable system including grade
(WHO 1973), stage, CIS, multiplicity, size, and previous
recurrence rate [5]. Although the EORTC risk score repre-
sents a major improvement, it does not fully capture
tumor heterogeneity of T1 NMIBC.
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Another approach has been to identify biomarkers to
predict the probability of progression in T1 NMIBC [6].
Cell cycle modulators are often deregulated in bladder
cancer, including alterations in various proteins such as
p53, CCNB1, p16, and p27 [6, 7]. p53 is frequently mu-
tated in patients with bladder cancer [8, 9]. Compared
with the wild-type protein, mutant p53 proteins have a
prolonged half-life and are thus more likely to be de-
tected by immunohistochemical assays [10]. In bladder
cancer, because of the high concordance between p53
nuclear immunoreactivity and genomic mutations, im-
munohistochemistry is a useful surrogate for examining
p53 mutation status [9, 11]. The value of pretreatment
p53 status on the progression of T1 NMIBC has been
studied and discussed. As a result, several studies repor-
ted that p53 overexpression is positively associated with
progression of T1 NMIBC [12, 13]. However, some studies
failed to confirm the association between p53 overexpres-
sion and progression of T1 NMIBC [14, 15].
Considering the inconsistent results of published arti-
cles, we conducted a meta-analysis to determine the p53
status in predicting progression of T1 NMIBC.
Methods
Search strategy
We conducted and reported this meta-analysis following
the PRISMA statement. A MEDLINE, EMBASE, and
Web of Science search for studies investigating the pro-
gression significance of p53 in T1 bladder cancer was
performed using the following keywords: [urinary blad-
der neoplasms] OR [urinary AND bladder AND neo-
plasms] OR [bladder AND cancer] OR [bladder cancer]
AND [T1] AND [p53] OR [TP53] AND [progression].
The final search was conducted on October 10, 2015.
Searches were limited to studies published in English.
The eligible publications were selected by two reviewers.
Inclusion and exclusion criteria
Studies were considered eligible if they met the following
inclusion criteria: (1) the study included proven diagno-
sis of urothelial carcinoma; (2) the study considered
TURBT as a treatment modality; (3) the study assessed
the association between p53 and progression of patients
with T1 bladder cancer; (4) to detect p53 status in the
primary tumor tissues using immunohistochemistry
(IHC); and (5) the study provided the data that showed
number of events. Studies were excluded based on any
of the following criteria: (1) review articles, commentar-
ies, letters to the editor, or case reports or (2) laboratory
studies, such as studies on bladder cancer cell lines and
animal models; for overlapping studies, the most recent
or most complete study was used to avoid duplication of
information.
Data extraction
According to the inclusion criteria listed above, data
were extracted independently by two reviewers for each
eligible study. We extracted data including (1) study
information including the name of first author, year of
publication, sample size, and time of research; (2) patient
characters including grade and intravesical therapy; (3)
p53 antibody clone and cutoff value of positivity of p53;
and (4) progression data (number of events).
Study quality assessment
Quality assessment of included studies was evaluated by
two independent reviewers (DJ and WSH) with the
Newcastle-Ottawa quality assessment scale (NOS) range
from 0 to 8 which is used in the evaluation of non-
randomized studies. Studies with an NOS score ≥6 were
assigned as high-quality studies. Studies from conference
abstracts and with score of zero were defined as low-
quality studies. Discordant studies were evaluated by the
two reviewers together.
Statistical analysis
The main outcome measures for this meta-analysis were
rates of progression. The primary aim was to search the
effect of p53 status (positive or negative) detected by
IHC on progression rates. For dichotomous data, a sum-
mary risk ratio (RR) and its 95 % CI were calculated. An
observed HR >1 implied progression for the study group
with positive p53, relative to the negative group. Sub-
group analyses were performed to examine if our pooled
estimate of the prognostic value was influenced by a test
of heterogeneity of the combined HRs, carried out using
the Chi-square test and I-squared statistic. A P > 0.10 for
the Chi-square test and an I2 value of <25 % was consid-
ered to represent a low level of heterogeneity between
studies. I2 > 50 % indicated large heterogeneity among
studies, whereas I2 values between 25 and 50 % indicated
moderate heterogeneity [16]. Sensitivity analysis was also
performed by removing one study at a time to calculate
the overall homogeneity and effect size; the Galbraith
plot was also performed to examine the possible distinct
articles. Publication bias was estimated with a visual in-
spection of funnel plots. All 95 % CIs were two-sided. The
meta-analysis was performed using Review Manager (Rev-
Man) software version 5.2 (RevMan 5.2; the Nordic




Through electronic screening, 151 potentially relevant
articles consistent with our searching terms were identi-
fied and 106 of them were eliminated after reading the
abstracts. Of the 45 article that were in full-text format,
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24 were excluded because of not including progression
data; 9 were excluded since there were no specific result
about p53 status in T1 NMIBC. The flowchart of select-
ing the procedure and the exclusive reason of studies is
summarized in Fig. 1. A total of 12 studies were included
in the meta-analysis (Table 1).
Quality assessment
Quality assessment of the 12 studies included in the meta-
analysis was performed by using NOS. In this quality as-
sessment system, scores 0–3, 4–5, and 6–8 are accepted
as low, medium, and high quality, respectively. The me-
dian score of the studies included in the meta-analysis was
found as 7.
Heterogeneity assessment
Meta-analysis of the correlation between p53 overexpres-
sion with progression of T1 NMIBC resulted in P < 0.0001
and I2 = 39 %, suggesting that there was moderate hetero-
geneity and that the subgroup analysis should be carried
out. Hence, we carried out subgroup analysis according to
stage, intravesical therapy, antibody clone, cutoff value of
positivity of p53, and ethnicity. However, none of these
factors was found to be significantly correlated to hetero-
geneity using subgroup analysis among the studies.
Meta-analysis results
Pooled analysis
p53 overexpression and progression of T1 NMIBC
There were 12 studies with a total of 712 patients included
in final analysis to assess the effect of p53 overexpression
on progression of T1 NMIBC. As shown in Fig. 2,
the pooled RR was 2.32 (95 % CI 1.59–3.38) by
random-effects model for the existence of a moderate
heterogeneity (I2 = 39 %, P < 0.0001), which suggested p53
overexpression was associated with progression of T1
NMIBC. Subgroup analysis according to grade, intravesi-
cal therapy, antibody clone, cutoff value of positivity of
p53, and ethnicity was also performed (Table 2). The
results suggested that all of the relevant stratified factors
did not have a significant correlation with heterogeneity
(P ranging from 0.18 to 0.63) and did not alter the signifi-
cant prognostic impact of p53 overexpression.
Subgroup analysis
p53 overexpression and progression of T1G3 NMIBC
There were 3 studies that included a total of 141 pure
T1 grade 3 (T1G3) NMIBC patients; the RR was 2.71
(95 % CI 1.31–5.64) by random-effects model for the ex-
istence of no heterogeneity (I2 = 0 %, P = 0.007), which
suggested p53 overexpression was associated with pro-
gression of T1G3 NMIBC (Table 2).
p53 overexpression and progression of T1 NMIBC
treated with BCG There were 4 studies that included a
total of 286 pure T1 NMIBC patients treated with Bacil-
lus Calmette-Guérin (BCG) intravesical therapy; the RR
was 2.71 (95 % CI 1.31–5.64) by random-effects model for
the existence of no heterogeneity (I2 = 0 %, P < 0.0001),
which suggested p53 overexpression was associated with
progression of T1 NMIBC patients treated with BCG






















Records identified through database searching
(n=297)






Full-text articles assessed 
for eligibility 
(n=45)
Full-text articles excluded, 
with reasons
(n=33)
Studies included in 
meta-analysis
(n=12)
Fig. 1 Flowchart of study selection
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Publication bias assessment and sensitivity analysis
Investigation of bias by a funnel plot showed no evi-
dence of significant publication bias among the studies
with respect to the effect of p53 status on progression of
T1 NMIBC (Fig. 3).
Sensitivity analysis was conducted to assess the influ-
ence of individual study on the pooled effect. One study
by Vatne et al. was identified in the Galbraith plot as the
outliers (Fig. 4). When we removed the study by Vatne
et al., the initial heterogeneity (I2 = 39 %, P < 0.0001) was
reduced to none (I2 = 0 %, P = 0.63) in evaluating the
association of p53 overexpression and progression of T1
NMIBC patients (Table 3).
Discussion
T1 NMIBC are potentially more lethal because approxi-
mately 40 % of tumors managed conservatively progress
to MIBC or develop distant metastasis within 5 years
[3]. Molecular markers are promising for accurately pre-
dicting the progression of T1 NMIBC patients. p53 plays
an important role in the regulation of cell cycle and
apoptosis. To date, the majority of available clinical re-
ports have involved small sample sizes and given conflict-
ing results, therefore unable to determine the value of p53
status in predicting progression of T1 NMIBC. Thus, we
conducted a meta-analysis of 12 studies to systematically
evaluate the association between p53 status and progres-
sion of T1 NMIBC.
To the best of our knowledge, this is the first meta-
analysis to evaluate the relationship between p53 status
and the progression of T1 NMIBC. In the overall pooled
analysis of the association of p53 status with progression
of T1 NMIBC, the results suggested that p53 overex-
pression associated with progression of T1 NMIBC.
Table 1 Studies included in the meta-analysis
Study Year Country p53 (+) p53 (−) No. of patients Cutoff (%) Antibody Intravesical therapy Quality score
Park [21] 2013 Korea 32 29 61 10 DO7 Pure BCG 7
Dalbagni [14] 2007 USA 53 36 89 20 Pab1801 Non-pure 5.5
Saint [12] 2004 France 24 78 102 20 DO7 Pure BCG 6
Lopez-Beltran [29] 2004 Spain 22 29 51 6 Pab1801 Pure BCG 7
Gil [15] 2003 Spain 40 27 67 20 DO7 Non-pure 7
Peyromaure [22] 2002 France 18 11 29 20 DO7 Pure BCG 6
Liopis [13] 2000 Spain 24 56 80 20 Bp-53-12-1 Non-pure 8
Shariat [30] 2000 USA 26 10 36 10 DO7 Non-pure 7
Toktas [31] 1999 Turkey 18 34 36 10 DO7 Non-pure 6
Pages [23] 1998 France 27 16 43 10 DO7 Pure BCG 6
Vatne [32] 1995 Norway 40 19 59 20 DO1 Non-pure 7
Sarkis [8] 1993 USA 25 18 43 20 Pab1801 Non-pure 7
Fig. 2 Forest plots of RRs estimated for the relationship between p53 overexpression and progression of T1 NMIBC patients
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In the test of heterogeneity, there was a moderate het-
erogeneity (I2 = 39 %) in the analysis of the association
of p53 status with progression of T1 NMIBC. Although
the data were aggregated using the random-effects
models, heterogeneity among the studies continued to
be a potential problem to influence the reliability of
pooled results. Hence, we carried out subgroup analysis
according to grade, intravesical therapy, antibody clone,
cutoff value of positivity of p53, and ethnicity. However,
none of these factors was found to be significantly corre-
lated to heterogeneity using a subgroup analysis.
However, there is no heterogeneity in T1G3 NMIBC
(I2 = 0 %); it suggested that p53 overexpression was associ-
ated with incremental progression of T1G3 NMIBC.
T1G3 NMIBC is one subtype of NMIBC, with the highest
progression risk [17]. Because T1G3 NMIBC can present
clinical characteristics of invasive tumors and clinical T1
tumors contain a variable proportion of understaged pT2
tumors, long-term rates of cancer-specific mortality reach
up to 34 % [18]. Expert recommendations on the optimal
treatment strategy for patients with T1G3 NMIBC range
from conservative intravesical therapy to early radical
Table 2 Summarized RRs of overall and subgroup analysis for T1 NMIBC patients with p53 overexpression
Variables No. of studies Random effects
RR (95 % CI)
Heterogeneity Subgroup analysis
P valueI2 (%) P value
Overall 12 2.41 (1.55, 3.75) 42 0.06 <0.0001
Ethnicity 0.44
Asian 2 3.09 (1.48, 6.46) 0 0.003
Non-Asian 10 2.20 (1.41, 3.45) 46 0.0005
Stage 0.63
T1G3 3 2.71 (1.31, 5.64) 0 0.007
All NMIBC 9 2.24 (1.40, 3.59) 52 0.0008
Intravesical therapy 0.18
Pure BCG 5 3.35 (1.89, 5.93) 0 <0.0001
Non-pure 7 1.97 (1.17, 3.33) 57 0.03
Antibody 0.49
DO7 7 2.59 (1.64, 4.08) 0 <0.0001
Pab1801 3 3.38 (1.73, 6.60) 0 0.0003
Others 2 1.38 (0.36, 5.34) 89 0.002
Cutoff 0.41
20 % 7 2.68 (1.92, 3.74) 9 <0.0001
Others 5 1.83 (0.78, 4.26) 51 0.16
Fig. 3 Publication bias determination using funnel plot
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cystectomy [18, 19]. Underestimation of the potential for
progression in T1G3 NMIBC could lead to unpreventable
morbidity and mortality; however, patients treated with
early radical cystectomy faced increased perioperative
mortality and decreased quality-of-life. Therefore, T1G3
NMIBC patients with p53 overexpression may probably
obtain better benefit from early radical cystectomy.
In addition, we did not observe heterogeneity in pa-
tients treated with BCG intravesical therapy (I2 = 0 %); it
suggested that p53 overexpression was associated with
elevated progression of T1 NMIBC received by BCG
intravesical therapy. Several investigators have evaluated
the prognostic value of nuclear p53 immunoreactivity
before BCG intravesical therapy. A correlation between
pretreatment p53 overexpression and disease progression
after BCG therapy was found in several studies [12, 20].
Other authors found no such correlation [21–26]. Never-
theless, it was found that BCG treatment was less likely to
be successful in patients with mutated p53 by using yeast
functional assay [27]. To date, whether p53 tumor status
is an independent predictive factor of BCG response in T1
NMIBC still remains a debate. The present meta-analysis
suggested that T1 NMIBC patients with p53 overexpres-
sion have increased progression risk after BCG intravesical
therapy; early radical cystectomy could be considered in
these patients.
It should be noted that our meta-analysis has several
limitations. First, this meta-analysis was limited by the
presence of heterogeneity across the studies. The hetero-
geneity possibly caused by the differences in the charac-
teristics of the patients, IHC technique, cutoff values,
and follow-up time. Second, to reduce the bias from dif-
ferent detection methods, we only included the studies
measuring p53 expression by IHC. IHC has been widely
used to detect molecular markers, because the method
is simple, fast, and reliable [28]. However, the differences
of the clones of antibody, concentration, and cutoff
value used in different studies might also cause potential
bias. Especially, the cutoff used to define p53 overex-
pression is probably of prime importance. In the present
meta-analysis, most of the studies chose a cutoff value of
20 %; p53 overexpression was a predictor of progression
in T1 NMIBC, and there is low heterogeneity among
these studies (I2 = 9 %, P < 0.0001). It suggested that a
cutoff value of 20 % may be a proper cutoff of p53. Fur-
thermore, the interpretation of immunohistochemical
results may vary among different centers. It is, therefore,
necessary to define a standard evaluation system to pro-
mote the application of p53 detected by IHC in clinical
practice. Third, the meta-analysis may have been influ-
enced by publication bias, as we limited the literature
search to studies performed in English. Finally, most of
the included studies were observational trials, which
contained more potential confounders and provided the
lower level of evidence compared with randomized con-
trolled studies. Therefore, the results should be inter-
preted cautiously.
Conclusions
The present study is the first meta-analysis to quantita-
tively assess the association between p53 status and pro-
gression of T1 NMIBC. The results showed that p53
overexpression might be a useful predictive biomarker
Fig. 4 Galbraith plot of association between p53 overexpression and T1 NMIBC patient progression risk
Table 3 Results of sensitivity analysis
Sensitivity analysis Heterogeneity Pooled analysis
I2 (%) P value RR (95 % CI) P value
Include Vatne et al.’s study 39 0.08 2.32 (1.59, 3.38) <0.0001
Exclude Vatne et al.’s study 0 0.67 2.74 (2.05, 3.65) <0.0001
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for evaluating progression in T1 NMIBC patients, espe-
cially in T1G3 NMIBC and patients treated by BCG
intravesical therapy. However, to strengthen our findings,
further larger prospective studies with better standardized
methods are needed to make a comprehensive conclusion
on the prognostic role of p53 overexpression in T1
NMIBC.
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